Sponsors

Molecular diagnostics from Mobidiag

Mobidiag develops and markets molecular diagnostics for gastrointestinal infections, antimicrobial resistance management, healthcare-associated infections and respiratory infections (including COVID-19).

The company aims to provide a global solution to clinicians, suited for their own laboratory needs and capacities.

Following the COVID-19 crisis, Mobidiag has harnessed its existing technologies and expertise to develop and supply coronavirus molecular diagnostic tests. In addition to targeted tests for COVID-19, it is now offering RESP-4 multiplex panels, which are highly relevant to both the traditional influenza season and COVID-19.

Symptoms caused by most common winter season viruses (SARS-CoV-2, Influenza A, Influenza B and RSV) can be very similar, and it is imperative that healthcare professionals are able to distinguish between them rapidly, in order to start the appropriate treatment. Amplidiag RESP-4 (for batch testing) and Novodiag RESP-4 (for on-demand testing) are now available.

www.mobidiag.com

Latest Issues

Annual SHOT Symposium

Hilton Birmingham Metropole Hotel, B40 1P
11 July 2025

IHC technical issues masterclass

UK NEQAS CPT, The Haylofts, Newcastle
13 August, 2025